Recent reports suggest a potential benefit of ezetimibe on non-alcoholic fatty liver disease (NAFLD) by improving hepatic insulin sensitivity and decreasing lipid accumulation and hepatic inflammation [37]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.